Cell and gene therapy (CGT) technologies have the potential to enable many individuals with rare diseases to live without the need for ongoing treatment and many patients with relapsing or refractory cancers to live longer. However, CGT treatments differ from traditional treatments, and new considerations must be taken into account for access.
The website sections, Cell and Gene Therapies versus Chronic Therapies and Precision Financing Solutions cover payment as an access barrier. Access to treatment payment alone, however, cannot remove all the barriers to care. Specialization for product administration, novel of duration of benefit, and even use of Precision Financing Solutions set further access hurdles for CGT.
FoCUS has provided an understanding of these differences and offered tools to help address barriers to care.